0000000000372502

AUTHOR

Moroni M

showing 3 related works from this author

Consensus document on controversial issues for the treatment of hospital-associated pneumonia

2010

Background: Hospital-associated pneumonia (HAP) remains an important cause of morbidity and mortality despite advances in antimicrobial therapy. Many aspects of the treatment of HAP caused by multi-resistant Gram-positive microorganisms have been extensively studied, but controversial issues remain. Controversial issues: The aim of this GISIG (Gruppo Italiano di Studio sulle Infezioni Gravi) working group – a panel of multidisciplinary experts – was to define recommendations for some controversial issues using an evidence-based and analytical approach. The controversial issues were: (1) Is combination antibiotic therapy or monotherapy more effective in the treatment of HAP? (2) What role do…

Microbiology (medical)medicine.medical_specialtyMEDLINECochrane LibraryGram-Positive BacteriaNosocomial pneumonia Health care-associated pneumonia 16Methicillin-resistant staphylococcilaw.inventionHealth care-associated pneumoniaRandomized controlled triallawSettore MED/41 - ANESTESIOLOGIAPneumonia BacterialHumansMedicineNOSOCOMIAL PNEUMONIAMethicillin-resistant staphylococciIntensive care medicineGram-Positive Bacterial InfectionsRandomized Controlled Trials as TopicCross InfectionEvidence-Based Medicinebusiness.industryBacterial pneumoniaRetrospective cohort studyGeneral MedicineEvidence-based medicinemedicine.diseaseAnti-Bacterial AgentsQuality of evidencePneumoniaTreatment OutcomeInfectious DiseasesDrug Therapy CombinationbusinessInternational Journal of Infectious Diseases
researchProduct

Survey of neonatal respiratory care and surfactant administration in very preterm infants in the Italian neonatal network

2013

INTRODUCTION: Variation of respiratory care is described between centers around the world. The Italian Neonatal Network (INN), as a national group of the Vermont-Oxford Network (VON) allows to perform a wide analysis of respiratory care in very low birth weight infants. METHODS: We analyzed the dataset of infants enrolled in the INN in 2009 and 2010 and, for surfactant administration only, from 2006 to 2010 from 83 participating centers. All definitions are those of the (VON). A questionnaire analysis was also performed with a questionnaire on centers practices. RESULTS: We report data for 8297 infants. Data on ventilator practices and outcomes are outlined. Variation for both practices and…

Preterm infants; Ventilation; Ventilatory support; Medicine (all)Drug Utilization; Humans; Infant Mortality; Infant Newborn; Infant Very Low Birth Weight; Intubation Intratracheal; Italy; Oxygen Inhalation Therapy; Pulmonary Surfactants; Respiration Artificial; Infant PrematureSettore MED/38 - Pediatria Generale E SpecialisticaInfant MortalityIntubation IntratrachealHumansInfant Very Low Birth WeightPrematureVery Low Birth WeightRespirationMedicine (all)Infant NewbornOxygen Inhalation TherapyInfantPreterm infantsPulmonary SurfactantsNewbornRespiration ArtificialDrug UtilizationVentilationnational survayIntratrachealVery preterm infant national survay neonatal respiratory careVentilatory supportItalyVery preterm infantArtificialPreterm infantneonatal respiratory careIntubationInfant Premature
researchProduct

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are creat…

2009

Contains fulltext : 80963.pdf (Publisher’s version ) (Open Access) BACKGROUND: The extent to which mortality differs following individual acquired immunodeficiency syndrome (AIDS)-defining events (ADEs) has not been assessed among patients initiating combination antiretroviral therapy. METHODS: We analyzed data from 31,620 patients with no prior ADEs who started combination antiretroviral therapy. Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE that occurred in >50 patients, after stratification by cohort and adjustment for sex, HIV transmission group, number of antiretroviral drugs initiated, regimen, age, date of starting combination antiretrovir…

MaleInfectious diseases and international health [NCEBP 13]Lymphoma030312 virologyEsophageal candidiasisCohort Studies0302 clinical medicineInterquartile range030212 general & internal medicineAIDS-RelatedLymphoma AIDS-Related0303 health sciencesMortality rateProgressive multifocal leukoencephalopathyHazard ratioPrognosis3. Good healthPathogenesis and modulation of inflammation [N4i 1]Infectious DiseasesCombinationDrug Therapy CombinationFemaleInfection and autoimmunity [NCMLS 1]HumanMicrobiology (medical)Adultmedicine.medical_specialtyPrognosiAnti-HIV Agentsantiretroviral therapyInfectious DiseaseArticleAIDS-Related Opportunistic Infection03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)Drug TherapyInternal medicinemedicineHumansAIDS-defining eventProportional Hazards ModelsAIDS-Related Opportunistic Infections/diagnosis/ mortality; Acquired Immunodeficiency Syndrome/complications/diagnosis/drug; therapy/ mortality; Adult; Anti-HIV Agents/ therapeutic use; Cohort Studies; Drug Therapy; Combination; Female; Humans; Lymphoma; AIDS-Related/diagnosis/mortality; Male; Prognosis; Proportional Hazards ModelsAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic Infectionsbusiness.industryProportional hazards modelPoverty-related infectious diseases [N4i 3]Anti-HIV Agentmedicine.diseasemortalityConfidence intervalImmunologyProportional Hazards ModelCohort Studiebusiness
researchProduct